Physician profile

Smith Joseph

Internal Medicine · North Miami, FL

NPI 1851376552

$234.72

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$155.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $58.70 2024 Repatha, Otezla
Exact Sciences Corporation $48.07 2023 Cologuard Collection Kit
Pfizer INC. $34.35 2023
Boehringer Ingelheim Pharmaceuticals, INC. $20.70 2021
Glaxosmithkline, LLC. $20.00 2021
Janssen Pharmaceuticals, INC $19.78 2019
Amarin Pharma, INC. $18.78 2019
Boston Scientific Corporation $14.34 2024 Watchman Access System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Smith Joseph

$234.72

in general payments reported 2019-2025

Years
2019-2024
Top company
Amgen INC.

https://glasscript.com/doctor/128811/smith-joseph

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.